Abstract: This disclosure relates to biomarkers for Age-Related Macular Degeneration (AMD) and methods of use thereof, e.g., methods of the use of biomarkers for determining that a subject has Age-related Macular Degeneration (AMD) or determining the stage of AMD in a subject.

Abstract: The disclosure features methods and systems that include: obtaining an input image of an imaging subject, where the input image is a color image featuring, in each of multiple color channels, a first set of pixel intensity values; for each one of the multiple color channels, determining a measured contrast value and a measured brightness value from the first set of pixel intensity values for the color channel, determining a contrast ratio for the color channel based on a target contrast value for the color channel and the measured contrast value for the color channel, and generating a second set of pixel intensity values for the color channel; and generating an output image of the imaging subject based on the second sets of pixel intensity values for each of the multiple color channels.

Abstract: This disclosure relates to biomarkers for Age-Related Macular Degeneration (AMD) and methods of use thereof, e.g., methods of the use of biomarkers for determining that a subject has Age-related Macular Degeneration (AMD) or determining the stage of AMD in a subject.

Abstract: The disclosure features methods and systems that include: obtaining an input image of an imaging subject, where the input image is a color image featuring, in each of multiple color channels, a first set of pixel intensity values; for each one of the multiple color channels, determining a measured contrast value and a measured brightness value from the first set of pixel intensity values for the color channel, determining a contrast ratio for the color channel based on a target contrast value for the color channel and the measured contrast value for the color channel, and generating a second set of pixel intensity values for the color channel; and generating an output image of the imaging subject based on the second sets of pixel intensity values for each of the multiple color channels.

Abstract: The invention provides a photodynamic therapy-based method for treating ocular glaucoma. A photosensitizer, for example, a benzoporphyrin derivative photosensitizer, is administered to a mammal either having or at risk of developing ocular glaucoma. The photosensitizer, when present in the ciliary body, is activated by light, for example, light from a laser. The treatment results in a reduction of intraocular pressure within the treated eye, which can persist for a prolonged period of time.

Abstract: The invention provides a photodynamic therapy-based method for treating ocular glaucoma. A photosensitizer, for example, a benzoporphyrin derivative photosensitizer, is administered to a mammal either having or at risk of developing ocular glaucoma. The photosensitizer, when present in the ciliary body, is activated by light, for example, light from a laser. The treatment results in a reduction of intraocular pressure within the treated eye, which can persist for a prolonged period of time.

Abstract: The invention provides a photodynamic therapy-based method for treating ocular glaucoma. A photosensitizer, for example, a benzoporphyrin derivative photosensitizer, is administered to a mammal either having or at risk of developing ocular glaucoma. The photosensitizer, when present in the ciliary body, is activated by light, for example, light from a laser. The treatment results in a reduction of intraocular pressure within the treated eye, which can persist for a prolonged period of time.